title: [Evaluation and management of acute radiation dermatitis].
abstract: Acute radiation dermatitis remains one of the most commonly observed side effect during radiation therapy leading to complication such as superinfection or treatment disruption. Its management is characterized by a great heterogeneity. Few strategies have demonstrated a benefit in preventing radiation dermatitis, which relies mostly on decreasing dose delivered to the skin and skin care practices. Simple emollients and use of topical steroids can be useful in early stages. The singularity of the skin toxicity seen with cetuximab and radiotherapy warrants a specific grading system and distinctive clinical treatment with use of antibiotics.
authors: Département de radiothérapie, institut Claudius-Regaud, Toulouse, France.
authors: A
authors: A
authors: Modesto
authors: J-C
authors: JC
authors: Faivre
authors: F
authors: F
authors: Granel-Brocard
authors: Y-G
authors: YG
authors: Tao
authors: Y
authors: Y
authors: Pointreau
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D047070:Bandages, Hydrocolloid; D020838:Calendula; D000068818:Cetuximab; D003879:Dermatologic Agents / Q000627:therapeutic use; D004801:Eosine Yellowish-(YS) / Q000627:therapeutic use; D004983:Ethanolamines / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D008517:Phytotherapy; D011855:Radiodermatitis / Q000145:classification / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012720:Severity of Illness Index; D017592:Skin Care
chemical_list: D000276:Adjuvants, Immunologic; D000700:Analgesics; D000891:Anti-Infective Agents, Local; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D004983:Ethanolamines; D005938:Glucocorticoids; D006820:Hyaluronic Acid; C009546:triethanolamine; D000068818:Cetuximab; D004801:Eosine Yellowish-(YS); D008775:Methylprednisolone